Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2ACS MEDICINAL CHEMISTRY LETTERSIF42017-01-2428OAAI
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of InfluenzaACS MEDICINAL CHEMISTRY LETTERSIF42017-01-2350OAAI
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 InhibitorsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52015-10-0112OAAI
Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 SubunitANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52015-03-01174OAAI
Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2JOURNAL OF MEDICINAL CHEMISTRYIF6.82014-07-24208PREAI
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjectsJOURNAL OF INFECTIOUS DISEASESIF4.52008-09-15197OAAI
Natural prevalence of HCV variants with decreased susceptibility to NS3-4A protease inhibitors in treatment-naive subjectsJOURNAL OF HEPATOLOGYIF332008-01-015PREAI
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine proteaseANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52006-03-01379OAAI